HighVista Strategies’s Centessa Pharmaceuticals CNTA Stock Holding History

HighVista Strategies’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$237K	Sell	5,964 -38,526	-87%	-$985K	0.07%	156
2025 Q4	$1.11M	Sell	44,490 -18,811	-30%	-$476K	0.29%	101
2025 Q3	$1.54M	Buy	63,301 +22,617	+56%	+$402K	0.38%	80
2025 Q2	$535K	Buy	40,684 +1,664	+4%	+$21.1K	0.2%	122
2025 Q1	$561K	Sell	39,020 -7,096	-15%	-$116K	0.22%	123
2024 Q4	$772K	Hold	46,116	–	–	0.29%	110
2024 Q3	$737K	Buy	+46,116	New	+$565K	0.25%	107

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HighVista Strategies's CNTA Position: Q1 2026 in Review

HighVista Strategies reduced its Centessa Pharmaceuticals (CNTA) stake by 87% in Q1 2026, selling an estimated $985K and leaving 5,964 shares worth $237K. The position accounts for 0.07% of the portfolio, ranked #156.

HighVista Strategies first reported a position in CNTA in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.54M in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

HighVista Strategies held 5,964 shares of Centessa Pharmaceuticals worth $237K as of Q1 2026.
HighVista Strategies sold 38,526 Centessa Pharmaceuticals shares in Q1 2026, an estimated $985K.
Centessa Pharmaceuticals made up 0.07% of HighVista Strategies's portfolio in Q1 2026, its #156 holding.
HighVista Strategies first reported a position in Centessa Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
HighVista Strategies's Centessa Pharmaceuticals position peaked at $1.54M in Q3 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.